1,443 results
1,443 results
Explore creators, their resources and related reviews to research your next step.
Julie Yoo
0.0
Co-founder and Chief Product Officer of Kyruus Health and former Chief Product Officer at Clio Health. Julie Yoo is a pioneer in healthcare technology and AI applications for improving patient access and care coordination. She co-founded Kyruus, a platform that uses AI and analytics to help patients find the right healthcare providers and optimize healthcare delivery networks. Her work focuses on using artificial intelligence to reduce healthcare disparities, improve care navigation, and enhance patient experiences. Yoo has been instrumental in developing AI-powered provider matching systems that consider factors like clinical expertise, patient preferences, and appointment availability. She is a frequent speaker on healthcare innovation and has been recognized as a thought leader in digital health transformation. Her expertise spans product development, healthcare operations, and the practical implementation of AI systems in complex healthcare environments. She advocates for patient-centered AI solutions that address real-world challenges in healthcare access and delivery. Her work has helped millions of patients find appropriate care more efficiently while helping healthcare systems optimize their provider networks.
Dr. Nathan Pearson
0.0
Co-founder and CEO of Owkin, a federated learning company applying AI to medical research and drug discovery. Dr. Pearson has pioneered the use of federated learning in healthcare, enabling hospitals and research institutions to collaborate on AI research while keeping patient data secure and private. Owkin platform allows multiple medical centers to train machine learning models together without sharing sensitive data. His company has developed AI models for cancer diagnosis, treatment prediction, and drug development through partnerships with major pharmaceutical companies and academic medical centers. Dr. Pearson has been instrumental in advancing privacy-preserving AI techniques that address regulatory and ethical concerns in healthcare data sharing. Under his leadership, Owkin has raised significant funding and established collaborations with leading cancer centers worldwide. The company AI models have been applied to oncology research, rare disease studies, and clinical trial optimization. His vision for federated learning represents a paradigm shift in how medical AI research can be conducted at scale while protecting patient privacy and complying with healthcare regulations.
Tanay Tandon
0.0
Co-founder and CEO of Athelas, a healthcare AI company developing automated diagnostic tools and clinical workflows. Under his leadership, Athelas has created AI-powered systems for blood analysis, infection detection, and clinical documentation. The company remote patient monitoring platform uses computer vision and machine learning to analyze blood samples and vital signs, enabling faster diagnosis and treatment decisions. Tandon has been recognized as a Forbes 30 Under 30 honoree for his innovations in healthcare technology. His company has raised significant venture capital and deployed AI systems in hospitals and clinics across the United States. Athelas technology includes automated white blood cell counting, infection screening, and chronic disease monitoring through AI-powered home health devices. Tandon vision combines artificial intelligence with accessible healthcare delivery, particularly focusing on bringing diagnostic capabilities to underserved communities. He regularly speaks about the potential of AI to democratize healthcare and reduce costs while improving patient outcomes. His work represents a new generation of healthcare entrepreneurs leveraging AI to solve real-world clinical challenges.
Dr. Megan Scudellari
0.0
Science journalist and educator specializing in biotechnology, AI, and precision medicine. Dr. Scudellari is a prominent science communicator who explains complex biotech and AI concepts to broad audiences through her writing for Nature, Science, IEEE Spectrum, and other major publications. She has covered breakthrough developments in AI-powered drug discovery, CRISPR gene editing, personalized medicine, and computational biology. Her expertise spans the intersection of artificial intelligence and life sciences, making her insights valuable for understanding how AI is transforming biotechnology and healthcare. She regularly speaks at conferences about the future of AI in medicine and the ethical implications of biotechnology advances. Her writing has helped bridge the gap between complex scientific research and public understanding, particularly in areas like machine learning applications in genomics, AI-driven clinical trials, and the development of personalized therapies. She holds an MIT Science Writing fellowship and has been recognized for her excellence in science communication. Her work helps both scientists and the public understand the potential and limitations of AI in transforming human health.
Dr. Lily Peng
0.0
Product Manager and Research Scientist at Google Health, specializing in AI applications for medical imaging and healthcare. Dr. Peng leads development of machine learning systems for diabetic retinopathy screening, lung cancer detection, and other medical imaging applications. She has been instrumental in deploying AI systems in real clinical settings, including partnerships with hospitals in Thailand and India for diabetic eye disease screening. Her work focuses on creating AI tools that can be deployed in resource-limited settings to improve access to healthcare. Dr. Peng has published numerous papers on deep learning for medical imaging and has spoken extensively about the challenges and opportunities of implementing AI in healthcare systems worldwide. She is particularly known for her work on ensuring AI systems are robust and generalizable across different populations and clinical settings. Her research includes developing AI models for tuberculosis screening, cardiovascular disease prediction from retinal images, and automated analysis of pathology slides. She advocates for responsible AI development that addresses health disparities and improves outcomes for underserved populations.
Alex Zhavoronkov
0.0
CEO and Founder of Insilico Medicine, a leading AI-driven drug discovery company. Dr. Zhavoronkov has pioneered the application of deep learning and generative AI to pharmaceutical research, developing platforms that can identify novel drug targets, design new molecules, and predict clinical trial outcomes. His company has successfully used AI to discover potential treatments for fibrosis, cancer, and aging-related diseases. Insilico Medicine utilizes generative adversarial networks (GANs) and other advanced AI techniques to accelerate drug development from years to months. Dr. Zhavoronkov is also a prominent researcher in longevity science, applying AI to understand aging mechanisms and develop anti-aging therapeutics. He has published over 200 papers and is a frequent speaker at biotech and AI conferences worldwide. His work represents a new paradigm in pharmaceutical research where AI drives the entire drug discovery pipeline from target identification to clinical development. Under his leadership, Insilico Medicine has raised significant funding and established partnerships with major pharmaceutical companies to bring AI-designed drugs to market.
Dr. Zak Kohane
0.0
Professor at Harvard Medical School and Boston Children Hospital, Dr. Kohane is a pioneer in biomedical informatics and AI applications in pediatric healthcare. He leads research on using machine learning for clinical decision support, drug discovery, and personalized medicine. His work includes developing AI systems for analyzing electronic health records to improve patient outcomes, predicting adverse drug reactions, and identifying new therapeutic targets. Dr. Kohane has founded multiple healthcare AI companies and has been instrumental in advancing the field of computational medicine. He is particularly known for his work on federated learning in healthcare, allowing multiple hospitals to collaborate on AI research while protecting patient privacy. His research spans genomics, proteomics, and clinical data analysis, with a focus on translating AI research into practical clinical applications. He has published over 300 papers and serves on numerous editorial boards and advisory committees for healthcare AI initiatives. His work at Boston Children Hospital includes developing AI tools for pediatric intensive care and creating predictive models for childhood diseases.
Dr. Marzyeh Ghassemi
0.0
Assistant Professor at MIT CSAIL and a leading researcher in machine learning for healthcare. Dr. Ghassemi specializes in developing AI systems that can predict patient outcomes, improve clinical decision-making, and reduce healthcare disparities. Her research focuses on applying deep learning to electronic health records, medical imaging, and physiological time series data to predict clinical events like sepsis, mortality, and treatment responses. She has published extensively on bias in healthcare AI and works to ensure that machine learning systems are fair and equitable across different patient populations. Her work includes developing models for intensive care unit monitoring, predicting patient deterioration, and improving treatment recommendations. She is particularly known for her research on algorithmic fairness in healthcare AI and addressing issues of bias that can affect minority and underserved populations. Dr. Ghassemi also teaches courses on machine learning for healthcare and mentors students in developing ethical AI systems for medical applications. Her interdisciplinary approach combines computer science, medicine, and social justice to create AI that truly benefits all patients.
Dan Gilmore - Supply Chain Tech Expert
0.0
Senior supply chain technology analyst at SCXchange and author covering robotics, automation, and AI transformation in logistics. Known for his Five Pillars of Robotic Order Fulfillment framework and deep industry insights into warehouse technology adoption.
Dr. John Jumper
0.0
Senior Research Scientist at DeepMind and co-winner of the 2024 Nobel Prize in Chemistry for AlphaFold protein structure prediction. Dr. Jumper led the technical development of AlphaFold2, which achieved unprecedented accuracy in predicting how proteins fold into their three-dimensional structures. His breakthrough work has revolutionized structural biology and accelerated drug discovery by providing researchers with accurate protein structure predictions for virtually all known proteins. Before joining DeepMind, he completed his PhD in theoretical chemistry at the University of Chicago, focusing on quantum monte carlo methods. His expertise spans machine learning, computational biology, and quantum chemistry. The AlphaFold database, built on his innovations, has become an essential resource for researchers worldwide studying diseases, developing new medications, and understanding biological processes at the molecular level. His work represents a paradigm shift in computational biology, transforming a decades-old grand challenge into a practical tool for advancing human health.
Dr. Andres Sevtsuk
0.0
MIT researcher specializing in urban analytics and AI applications in real estate development. Leading academic expert in machine learning for property valuation and urban planning.
Daniel Lewis
0.0
Daniel Lewis is a leading legal technology strategist, author, and consultant who helps law firms and legal organizations navigate digital transformation and AI adoption. As the founder of How to Contract and author of multiple books on legal technology, Lewis provides insights into contract automation, AI implementation in legal practice, and the future of legal service delivery. His expertise spans contract lifecycle management, legal process optimization, and helping legal teams adopt AI tools for document review, contract analysis, and legal research. Lewis regularly speaks at legal technology conferences and writes extensively about practical AI applications in law, making complex legal technology concepts accessible to practicing attorneys and legal operations professionals. His consulting work focuses on helping law firms develop AI strategies, implement legal technology solutions, and train legal professionals on emerging AI tools that enhance legal practice efficiency and client service delivery.
Something missing?